GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Equity-to-Asset

Traws Pharma (FRA:0T2) Equity-to-Asset : 0.47 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Traws Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €9.79 Mil. Traws Pharma's Total Assets for the quarter that ended in Dec. 2023 was €20.80 Mil. Therefore, Traws Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.47.

The historical rank and industry rank for Traws Pharma's Equity-to-Asset or its related term are showing as below:

FRA:0T2' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.35   Med: 0.45   Max: 0.83
Current: 0.47

During the past 13 years, the highest Equity to Asset Ratio of Traws Pharma was 0.83. The lowest was -2.35. And the median was 0.45.

FRA:0T2's Equity-to-Asset is ranked worse than
66.47% of 1563 companies
in the Biotechnology industry
Industry Median: 0.66 vs FRA:0T2: 0.47

Traws Pharma Equity-to-Asset Historical Data

The historical data trend for Traws Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Equity-to-Asset Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.31 0.83 0.72 0.47

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.65 0.62 0.54 0.47

Competitive Comparison of Traws Pharma's Equity-to-Asset

For the Biotechnology subindustry, Traws Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Equity-to-Asset falls into.



Traws Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Traws Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=9.786/20.8
=0.47

Traws Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=9.786/20.8
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Traws Pharma  (FRA:0T2) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Traws Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (FRA:0T2) Business Description

Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines